Perrigo Loratadine 10 Mg 505(b)(2) Should Be Denied – Genpharm Petition
This article was originally published in The Tan Sheet
Executive Summary
FDA should "send a prompt letter ruling" to Perrigo denying approval of the firm's 505(b)(2) application for 10 mg loratadine tablets, according to an April 15 citizen petition submitted to the agency by Genpharm
You may also be interested in...
Schering Plans For Possible Clarinex Switch By Readying OTC Division
Preparations for a possible Rx-to-OTC switch of Clarinex (desloratadine) will be directed by Schering Consumer Health Care Division Chairman Stanley Barshay
Schering Plans For Possible Clarinex Switch By Readying OTC Division
Preparations for a possible Rx-to-OTC switch of Clarinex (desloratadine) will be directed by Schering Consumer Health Care Division Chairman Stanley Barshay
Schering Plans For Possible Clarinex Switch By Readying OTC Division
Preparations for a possible Rx-to-OTC switch of Clarinex (desloratadine) will be directed by Schering Consumer Health Care Division Chairman Stanley Barshay